The current study was designed to determine the minimal chain length of a heparin oligosaccharide that could significantly inhibit CXCL12-mediated breast cancer metastasis, while abrogating the potential anticoagulation problems associated with the use of heparin as an antimetastatic treatment. Here, CXCL12 is linked to breast cancer.